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Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease that causes
death of upper and lower motor neurons (MNs) in the central nervous system (CNS). The disease afflicts
most people in prime periods of productivity in life, and it is estimated approximately 200,000 individuals
in the United States live with ALS and any given time. Though a significant percentage of individuals with
ALS have a genetic or hereditary form of the disease, the majority are sporadic cases with unknown
etiologies. Regardless of cause, onset and progression of the disease is similar in all ALS patients, with
minor initial outward symptoms followed by rapid deterioration of motor function leading to widespread
paralysis, respiratory dysfunction and death. Despite the distressing and debilitating nature of ALS, no
cures and limited potential treatment options exist. Therefore, identifying targets for effective therapy
leading to delayed disease progression, increased quality of life, and extended lifespan are critical areas of
investigation. In addition, identifying biomarkers of disease progression is incredibly important as
diagnosis often occurs once the disease is in late stages and lifespan is only an average of 3–5 years after
diagnosis. As the cellular and physiological processes known to influence or be involved in ALS are
numerous, the complexity of the disease is a major detriment in developing effective therapies. Aside from
the ubiquitous death of MNs, inflammatory and immunologic response in the spinal cord, brain and target
muscles, and signal pathway changes that precede or are induced by MN death have been identified at
multiple stages of disease progression. As with most neural disorders and diseases, a multifactorial
approach to therapy is likely the most appropriate.
Stem cells are promising potential treatments for multiple conditions, and researchers have demonstrated
these effects broadly. Of these, adipose-derived stem cells (ASCs) are unique and have many benefits for
the treatment of neural injury and disease. ASCs are multipotent mesenchymal stem cells that are easily
obtained from adipose tissue. As such, isolating and purifying ASCs for autologous transplantation or
treatment is much more accessible than for bone marrow-derived stem cells or other mesenchymal stem
cells. Location and method of isolation influence the differentiation potential and other phenotypic
characteristics of ASCs, but most are readily obtained from subcutaneous fat via lipoaspiration. In general,
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isolated ASCs tend to express similar surface markers to pericytes, favor differentiation toward vascular
pericyte lineage, and evidence suggests these cells may be isolated from perivascular regions within the
adipose tissue (Traktuev et al., 2008). In spite of this seemingly vascular-centric nature of ASCs,
transplantation of these cells into neural tissue for studying their therapeutic effects has yielded variable
responses of ASCs to the local microenvironment that effect differentiation and cell fate.
In neural therapy, recent studies have shown benefits of CNS transplantation of ASCs in stroke and spinal
cord injury animal models. When transplanted into the spinal cord, ASCs have demonstrated the potential
to differentiate toward a neuronal phenotype and promote remodeling of the microenvironment of the
injured cord including promoting serotonergic axonal regeneration (Kolar et al., 2014). In a stroke model,
transplanted ASCs reduced cell death, infarct volume, and reduced inflammatory cytokine expression in
injured brain tissue when combined with mild hypothermia (Zhao et al., 2018). Though the
microenvironment affects the function and fate of ASCs following transplantation, their beneficial
properties arise from the paracrine effects of trophic and neurotrophic factor secretion by ASCs. This has
promoted exploration of the use of conditioned medium from cultured ASCs as a potentially less invasive,
yet still effective treatment paradigm.
Neuroprotective and regenerative effects of ASC conditioned medium (ASC-CM): ASC-CM has been
shown to be effective in the experimental treatment of a myriad of neurologic pathologies, injuries, and
conditions. Recent studies have demonstrated neuroprotective and regenerative effects of ASC-CM in
animal models of Parkinson’s disease, hypoxic-ischemic brain injury, and peripheral nerve injury. Our
research and studies by our collaborators have demonstrated that administration of human ASC-CM
maintains neuromuscular innervation when given prior to onset of this early pathology (Walker et al.,
2018), and late stage treatment (at symptom onset) has proven effective at reducing MN death, delaying
symptom progression, and extending lifespan in the classic mutant superoxide dismutase 1 (mSOD1)G93A
transgenic mouse model of ALS (Fontanilla et al., 2015). ASC-CM is a complex combination of paracrine
factors that could influence the CNS and peripheral neuromuscular interaction separately or
simultaneously in imparting such outcomes in this ALS mouse model.
ASC-CM is a cocktail of protective and growth-inducing proteins: Hundreds of proteins are secreted
by ASCs, and the benefits observed from ASC-CM therapy in neurological diseases have been attributed
or confirmed to be due in large part to the various trophic factors released from the cells into the medium.
Neuroprotective effects of ASC-CM are known to be highly influenced by the presence of brain-derived
neurotrophic factor (BDNF) (Wei et al., 2009), nerve growth factor (Fontanilla et al., 2015), insulin-like
growth factor-1 (IGF-1) (Wei et al., 2009), and glial cell line-derived neurotrophic factor (GDNF)
(Palomares et al., 2018). These findings are unsurprising, as individual trophic factors have long been
associated with protective or reparative effects in neurologic injury and disease, mostly in animal models.
Unfortunately, systemic and intrathecal administration of individual growth factors has shown limited or
conflicting therapeutic efficacy in ALS patients.
The most evidence related to clinical study of trophic factor delivery appears to be centered on BDNF and
IGF-1. Different types of administration and doses of IGF-1 and BDNF have been tried, though findings
have been difficult to interpret in the context of safety and treatment benefit. Ultimately, dosing issues and
side effects, such as paresthesia, have been a recurring problem with no therapeutic efficacy observed or
with modest influence on certain outcomes. In general, the overall view of such treatments is that any
single factor is likely not going to be therapeutically effective, especially in relation to the risks for
optimizing such approaches. A promising therapeutic aspect of ASC-CM, however, is the ability to
delivery several beneficial neurotrophic factors in one systemic treatment approach. In showing
neuroprotective, symptomatic and survival benefits in a mouse model of ALS, it is possible that many
different individual factors exhibited benefits, with nerve growth factor a noted contributor to these effects
(Fontanilla et al., 2015). As mentioned animal research showing evidence of therapeutic benefits of
individual trophic factors is common, though similar benefits are not replicated in clinical application. In
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our recent work, we demonstrated a clear peripheral influence of ASC-CM on the preservation of
innervated neuromuscular junctions (NMJs) when administered before and through a period of initial
neuromuscular disconnection in the mSOD1G93A mouse model of ALS (Walker et al., 2018), and any or
all of the listed trophic factors could have played a role in imparting this benefit. However, it is most likely
a synergistic collective effect dependent on the cocktail of factors, which is promising for overcoming
limitations of previous clinical trophic factor treatment paradigms.
Central versus peripheral effects of systemic ASC-CM: An important question in the treatment of ALS
with ASC-CM is whether peripheral benefits (e.g. NMJ innervation) involves only the treatment effects on
the target itself, or whether a central effect (e.g. neurotrophic stimulation of spinal cord motor neuron
innervating the muscle) may be involved. The effects of ASC-CM in the described studies resulted from
localized and systemic administration, which highlights the consideration of the state of the blood-brain
and blood-spinal cord barrier (BSCB) for practical application of ASC-CM from a clinical perspective.
Therefore, location and timing of treatment and pathological characteristics of disease progression
influence the efficacy of therapeutic ASC-CM administration.
Based on our observed effects of early treatment and NMJ preservation (Walker et al., 2018) and the
evidence of post-symptomatic treatment-induced MN survival and extended lifespan (Fontanilla et al.,
2015), these findings suggest systemic ASC-CM delivery could act on both central and peripheral
components of the nervous and neuromuscular systems. This idea is supported by previous research into
the disruption of the BSCB in the SOD1G93A mouse model of ALS. Zhong et al. (2008) demonstrated
that the BSCB is disrupted in the ALS mouse model as early as 60 days of age, a pre-symptomatic time
period before the observation of MN loss. As such, if the BSCB remains “leaky” from this period
throughout disease progression, large molecules like neurotrophic factors can reach typically restricted
intraparenchymal areas of the CNS microenvironment containing MN cell bodies and other cells. To our
knowledge, no earlier time points have been reported concerning the integrity of the BSCB in the
mSOD1G93A mouse model of ALS. Our preliminary evidence suggests that the BSCB may be disrupted
as early as 35 days of age, which is the date we began administration of ASC-CM in our investigation of
NMJ preservation in this mouse model (data not shown). As such, the effects we observed in the periphery
at the NMJ may have involved a central influence of ASC-CM. Recent research showed that BSCB barrier
repair could slow progression of motor neuron degeneration in the mSOD1G93A ALS mouse (Winkler et
al., 2014). Since Ad-MSCs are known to have pro-angiogenic and vasculature-associated properties, it
cannot be discounted that ASC-CM could help seal the leaky BSCB, contributing positively to the disease
in this way, as well.
Trophic regulation in the ventral horn of the spinal cord of ALS patients is known to be altered compared
to healthy individuals (Duberley et al., 1997). Part of this dysregulation in individuals with ALS involves
alterations in spinal ventral horn and motor neuron trophic factor receptor expression. In the ventral horn
of post-mortem ALS patient spinal cord, IGF-1 receptor expression was upregulated especially in the
ventral horn of cervical and sacral levels of the cord. This indicates that surviving neurons may be
responsive to IGF-1 in systemic ASC-CM treatment. Likewise, mRNA for trkB receptor, the receptor for
BDNF, is also upregulated in ventral horn spinal MNs in ALS patients (Seeburger et al., 1993). As ASC-
CM is known to contain these factors, systemic treatment may allow for a neuroprotective central effect on
the spinal motor neuron soma, in addition to possible peripheral influence on the muscle and NMJ.
As upper MNs, including corticospinal neurons, are also affected in disease progression and the blood
brain barrier disruption could span the entire CNS, it is possible ASC-CM may be influencing upper MN
health and survival as part of its mechanism of action. Concerning cerebral motor cortex upper MNs,
information concerning trophic factor and receptor expression is limited, as most studies have focused on
the lower MN. However, some research has provided potential insight into upper MN expression and
modulation of trophic factors in ALS and the neuronal response of MNs to these factors. In a study of
BDNF and neurotrophin-3 treatment, no difference was observed between localization of these factors in
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motor cortex neurons and those of healthy controls, indicating that the cortical influence of specific trophic
factors may not be as robust as observed in spinal MNs. This is supported by findings suggesting
neurotrophin-3 and BDNF treatment does not provide a neuroprotective response in cortical MNs (Van
Westerlaak et al., 2001); however this was an in vitro study, which restricts the extent of potential
interpretation. Information related to trophic factor receptor expression is even more limited; therefore, it
remains unclear how ASC-CM trophic factors may influence morphology and survival of upper MNs in
ALS. Though morphologic changes associated with neurodegeneration occur in cortical MNs in ALS,
further study is necessary concerning trophic factor production and response in these cells. This
information is required for more thorough investigation of the potential trophic influence of systemic
ASC-CM therapy on cortical upper MNs.
Future directions for ASC-CM therapy in ALS: ASC-CM is already in clinical trials for other
conditions, so it is quite conceivable based on benefits observed in animal models of ALS that it could be
effectively tested in ALS patients. Key issues of consideration are when to start treatment, length of
treatment and safety. As patients that are diagnosed first visit the clinic with outward symptoms, it is
generally considered that the disease is in such an advanced stage that treatments beginning at this point in
time will be of little benefit. This is reflected in the marginal and debatable benefits of currently approved
clinical therapies. In addition, if it is desirable to utilize one’s own ASCs for conditioned medium
collection, this requires additional time before treatment can begin. Despite these limitations, this is
currently the most feasible and clinically relevant approach for developing and testing treatments for ALS.
Our colleagues’ demonstration that systemic ASC-CM treatment after symptom onset imparts therapeutic
benefits is encouraging in this direction of application.
Research into identifying biomarkers for ALS has greatly increased in recent years, and if identified,
perhaps the disease can be detected and treatment started before progression into such advanced stages. As
ALS is primarily sporadic in nature, a biomarker-based screening approach will work best for those with a
genetic pre-disposition, such as a known hereditary SOD1 mutation. If the disease is diagnosed early
enough before advanced stages of disease progression, systemic ASC-CM may be even more beneficial
providing central neuroprotective or regenerative benefits and observable improvement in peripheral
innervation for delayed symptom progression and prolonged survival.
Concerning safety, in a broad view, little outward evidence suggests long-term administration of ASC-CM
is unsafe or has undesirable side effects. From an immunologic perspective, it is also a concern that
continued systemic treatment with ASC-CM could induce an immune response against factors in the
conditioned medium, decreasing the efficacy of treatment over time. Our initial investigation into the
immune system response to long-term ASC-CM therapy showed that there were no differences in
immunoglobulin isotype levels between ASC-CM-treated and vehicle-treated mSOD1G93A mice and
ASC-CM-treated non-transgenic mice (data not shown). This suggests some measure of safety and
possible continued efficacy of treatment over long periods of time; however, further studies are required to
obtain a broader understanding of the systemic influence of continued exposure to systemic ASC-CM.
How specific immune and glial cells may respond to long-term ASC-CM treatment also requires
additional study. In addition, much research has focused on the spinal lower MN, even though upper MNs
are also affected in ALS. As such, more general research into trophic function in cortical MNs and in the
microenvironment of the motor cortex is required. Though general research into the morphological and
survival benefits of ASC-CM on cortical upper MNs is possible, specific mechanistic information of how
these benefits are obtained will require a more established foundation of pathologic trophic factor and
receptor alteration in the motor cortex.
Conclusion: Systemic ASC-CM delivery is both effective in ameliorating disease progression in late-stage
ALS mice and beneficial in protecting NMJ denervation in early pre-symptomatic stages of disease,
however, research into ASC-CM as a therapy for ALS is in its infancy (Figure 1). Early pre-symptomatic
treatment affects initial neuromuscular denervation, but it is not known whether this benefit can contribute
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to long-term functional benefits. Post-symptomatic treatment is neuroprotective and extends lifespan in
mSOD1G93A mice, and reduced glial fibrillary acid protein expression implicates reduced inflammation
as part of the treatment effects (Fontanilla et al, 2015). As both peripheral and central effects are observed,
it is also unclear if the CNS or the neuromuscular interface is the primary site of therapeutic ASC-CM
influence. Perhaps a combination of treating both of these components is necessary for optimal therapeutic
efficacy. Lastly, how well the observed responses in the mouse model of ALS will translate to human
therapy remains to be investigated. We believe our research sets the foundation for further investigations
into the long-term benefits of early continuous ASC-CM treatment, as well as studies into therapeutic
effects when administered at intermediate stages of disease in the mSOD1G93A mouse model of ALS.
With a more thorough understanding of the different treatment effects, both positive and negative, in
animal models of disease, we anticipate that future clinical application and testing of ASC-CM treatment is
possible.
The foundational research performed by the labs of Dr. Keith March and colleagues is valuable to this
article. I thank Drs. March and Kathryn J. Jones for guidance and collaboration in the execution,
evaluation and continuation of the research directions proposed in this manuscript.
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Figure 1
What we know and do not know about ASC-CM therapy.
Post-symptomatic treatment with ASC-CM reduces intraspinal GFAP expression, increases motor neuron survival, and
prolongs lifespan, while early pre-symptomatic administration ameliorates NMJ denervation. The effects of ASC-CM on
upper motor neurons, how different durations of treatment influence long-term neurological and survival outcomes and
the primary sites of ASC-CM effects require further investigation. ASC-CM: Adipose-derived stem cell conditioned
medium; GFAP: glial fibrillary acidic protein; NMJ: neuromuscular junction; ASCs: adipose-derived stem cells.
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